These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 11036475)

  • 1. Tamoxifen for treatment of premenopausal women with breast cancer.
    Lam RY; Chlebowski RT
    Cancer Invest; 2000; 18(7):681-4. PubMed ID: 11036475
    [No Abstract]   [Full Text] [Related]  

  • 2. Tamoxifen in early breast cancer.
    Arriagada R
    Lancet; 1998 Aug; 352(9125):403-4. PubMed ID: 9717953
    [No Abstract]   [Full Text] [Related]  

  • 3. Optimizing endocrine therapy for breast cancer.
    Winer EP
    J Clin Oncol; 2005 Mar; 23(8):1609-10. PubMed ID: 15755964
    [No Abstract]   [Full Text] [Related]  

  • 4. Plasma lipids and lipoprotein alterations in tamoxifen-treated breast cancer women in relation to the menopausal status.
    Ilanchezhian S; Thangaraju M; Sachdanandam P
    Cancer Biochem Biophys; 1995 Nov; 15(2):83-90. PubMed ID: 8590439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
    Gnant M; Mlineritsch B; Schippinger W; Luschin-Ebengreuth G; Pöstlberger S; Menzel C; Jakesz R; Seifert M; Hubalek M; Bjelic-Radisic V; Samonigg H; Tausch C; Eidtmann H; Steger G; Kwasny W; Dubsky P; Fridrik M; Fitzal F; Stierer M; Rücklinger E; Greil R; ; Marth C
    N Engl J Med; 2009 Feb; 360(7):679-91. PubMed ID: 19213681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy of tamoxifen.
    Robert NJ
    Oncology (Williston Park); 1997 Feb; 11(2 Suppl 1):15-20. PubMed ID: 9065922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant tamoxifen versus tamoxifen plus CMF in the treatment of early breast cancer in Greece. Fifteen-year results of a randomised prospective trial and the potential risks of the antioestrogen.
    Vorgias G; Koukouras D; Tzoracoeleftherakis E; Paleogianni V; Androulakis J
    Anticancer Res; 2000; 20(5C):3849-54. PubMed ID: 11268466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative measurement of epidermal growth factor receptor is a negative predictive factor for tamoxifen response in hormone receptor positive premenopausal breast cancer.
    Giltnane JM; Rydén L; Cregger M; Bendahl PO; Jirström K; Rimm DL
    J Clin Oncol; 2007 Jul; 25(21):3007-14. PubMed ID: 17634479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer.
    Crump M; Sawka CA; DeBoer G; Buchanan RB; Ingle JN; Forbes J; Meakin JW; Shelley W; Pritchard KI
    Breast Cancer Res Treat; 1997 Jul; 44(3):201-10. PubMed ID: 9266099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of ovarian ablation in the management of breast cancer.
    Wirk B
    Breast J; 2005; 11(6):416-24. PubMed ID: 16297086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current and future roles of adjuvant endocrine therapy in the management of early carcinoma of the breast.
    Baum M; Benson JR
    Recent Results Cancer Res; 1996; 140():215-26. PubMed ID: 8787064
    [No Abstract]   [Full Text] [Related]  

  • 12. [Standards, Options and Recommendations (SOR) for endocrine therapy in patients with non metastatic breast cancer. FNCLCC].
    Mauriac L; Blanc-Vincent MP; Luporsi E; Cutuli B; Fourquet A; Garbay JR; Giard S; Spyratos F; Zafrani B; Dilhuydy JM
    Bull Cancer; 2000 Jun; 87(6):469-90. PubMed ID: 10903789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aromatase inhibitors for breast cancer: pharmacoeconomic considerations.
    Higa GM
    Expert Opin Pharmacother; 2001 Jun; 2(6):987-95. PubMed ID: 11585014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project.
    Pelizzari G; Arpino G; Biganzoli L; Cinieri S; De Laurentiis M; Del Mastro L; Di Leo A; Gori S; Guarneri V; Marchetti P; Puglisi F
    BMC Cancer; 2018 Sep; 18(1):932. PubMed ID: 30261866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Should tamoxifen be used to treat premenopausal women with breast cancer?
    Pritchard KI
    Cancer Invest; 2000; 18(7):685-6. PubMed ID: 11036476
    [No Abstract]   [Full Text] [Related]  

  • 16. Risks and benefits of tamoxifen therapy.
    Assikis VJ; Jordan VC
    Oncology (Williston Park); 1997 Feb; 11(2 Suppl 1):21-3. PubMed ID: 9065923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endocrine therapy in breast cancer.
    Johnson AE
    Lancet; 1996 Mar; 347(9003):761. PubMed ID: 8602017
    [No Abstract]   [Full Text] [Related]  

  • 18. [Tamoxifen and breast cancer: is everything known already?].
    Marchetti P; Porzio G; Trapasso T; Baldi PL; Ficorella C
    Tumori; 1998; 84(6):A1-5. PubMed ID: 10080686
    [No Abstract]   [Full Text] [Related]  

  • 19. Tamoxifen: five versus ten years--is the end in sight?
    Abrams JS
    J Natl Cancer Inst; 2001 May; 93(9):662-4. PubMed ID: 11333277
    [No Abstract]   [Full Text] [Related]  

  • 20. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer.
    Howell A; Robertson J
    Lancet; 1995 Apr; 345(8955):989-90. PubMed ID: 7772169
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.